Cyclacel Pharmaceuticals Inc.
13F holders, Q4 2024 (December 31)18holders +3
3new positions
1sold out
1famous investor
$0.38avg. 13F price*
At the end of Q4 2024, 18 institutions reported holding Cyclacel Pharmaceuticals Inc. in their 13F filings, up 3 from Q3 2024. 3 opened new positions and 1 sold out. The largest holders were Armistice Capital, LLC ($218K), UBS Group AG ($18K) and Two Sigma Securities, LLC ($11K). One famous investor held it Steve Cohen (0.0% of Point72 Asset Management's portfolio).
- Company
- Cyclacel Pharmaceuticals Inc.
- CUSIP
- 23254L801
- Latest filing quarter
- Q1 2025
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $11K |
| Exits | 1 | $164 |
All 13F filers, Q3 2024 → Q4 2024: 501,043 shares bought and 166 shares sold, net +500,877 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 18 holders
| Armistice Capital, LLC | 0.01% | Add +300.3% | 580,461 | $218K |
| UBS Group AG | 0.00% | Add +276.9% | 47,317 | $18K |
| Two Sigma Securities, LLC | 0.00% | New | 28,580 | $11K |
| Point72 Asset Management | 0.00% | No change | 15,333 | $6K |
| Acadian Asset Management LLC | 0.00% | No change | 14,285 | $5K |
| Geode Capital Management, LLC | 0.00% | Add +2.1% | 10,817 | $4K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +39.5% | 5,593 | $2K |
| SBI Securities Co., Ltd. | 0.00% | — | 802 | $302 |
| Financial Gravity Companies, Inc. | 0.00% | New | 200 | $75 |
| Archer Investment Corp | 0.00% | New | 200 | $75 |
| Activest Wealth Management | 0.00% | No change | 133 | $50 |
| Osaic Holdings, Inc. | 0.00% | No change | 126 | $47 |
| Morgan Stanley | 0.00% | No change | 80 | $30 |
| Bank of America Corp. | 0.00% | Add +240.0% | 51 | $19 |
| Wells Fargo & Company | 0.00% | No change | 33 | $12 |
| Signaturefd, LLC | 0.00% | No change | 20 | $8 |
| Harbour Investments, Inc. | 0.00% | No change | 13 | $5 |
| Danske Bank A/S | 0.00% | No change | 2 | $1 |
"% of holder's portfolio" is CYCLACEL PHARMACEUTICALS INC's weight in each manager's 13F, not the share of Cyclacel Pharmaceuticals Inc. the manager owns.